胸腔内抗肿瘤药物治疗非小细胞肺癌伴恶性胸腔积液的研究进展

Progress in the Treatment of Non-Small Cell Lung Cancer with Malignant Pleural Effusion with Intrathoracic Antitumor Agents

非小细胞肺癌伴恶性胸腔积液是一种严重的疾病,可导致呼吸困难、疼痛、恶病质和体力活动减少,非小细胞肺癌合并恶性胸腔积液的发生往往提示预后不佳。尽管目前有许多治疗方法可用于治疗恶性胸腔积液,但没有一种方法是完全有效的,大多数只能缓解患者的症状。胸腔内抗肿瘤药物治疗不仅能减少胸腔积液的渗出,还能够协同全身抗肿瘤作用。因此,研究胸腔内抗肿瘤药物治疗是对治疗非小细胞肺癌伴恶性胸腔积液患者的合理策略。本文通过系统地回顾和分析国内外文献,总结了目前胸腔内抗肿瘤药物治疗非小细胞肺癌伴恶性胸腔积液的研究进展。旨在为临床医生提供实用的治疗手段,进一步提高非小细胞肺癌伴恶性胸腔积液患者的生存率。Non-small cell lung cancer with malignant pleural effusion is a serious disease that can lead to dyspnea, pain, cachexia and reduced physical activity. The occurrence of malignant pleural effusion with non-small cell lung cancer often indicates a poor prognosis. Although many treatments are currently available to treat malignant pleural effusion, none are completely effective and most only relieve the patient’s symptoms. Intrathoracic antitumor drug therapy can not only reduce the effusion of pleural effusion, but also coordinate the anti-tumor effect of the whole body. Therefore, the study of intrathoracic antitumor therapy is a reasonable strategy for the treatment of patients with non-small cell lung cancer with malignant pleural effusion. Based on the systematic review and analysis of domestic and foreign literature, this paper summarizes the current research progress of intrathoracic antitumor drugs in the treatment of non-small cell lung cancer with malignant pleural effusion. The aim is to provide a practical treatment for clinicians and further improve the survival rate of patients with non-small cell lung cancer with malignant pleural effusion.